Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

PAR-25-082: Co-infection and Cancer (R01 Clinical Trial Not Allowed)

Closed Closed January 7, 2026 Opportunity PAR-25-082

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.

National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 7, 2026.

From the official notice on Grants.gov, last changed November 21, 2024. Checked November 7, 2026.

About this NIH notice

Projects funded under PAR-25-082 were run by National Cancer Institute (NCI, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read PAR-25-082 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
PAR-23-055December 14, 2022Closed October 17, 2024Closed

Key dates

PostedNovember 21, 2024
DeadlineJanuary 7, 2026
Archived by Grants.govFebruary 12, 2026

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to co-infections (excluding co-infection with human immunodeficiency virus [HIV]) that engendered novel opportunities for prevention and treatment and focus on understudied populations. Coinfection is defined as the occurrence of infections by two or more infectious (pathogenic or nonpathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms.

Category: Education, Health.

Funded under PAR-25-082 so far

NIH funded 2 projects under PAR-25-082 in fiscal 2026, at 2 institutions. The median yearly award was $560,544.

Recently funded projects
ProjectInstitutionFiscal yearAward
Modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer R01University of TX MD Anderson Can Ctr2026$660,541
Defining the pathogenesis of gammaherpesvirus and Plasmodium coinfections R01Univ of Arkansas for Med Scis2026$460,548

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Cancer Cause and Prevention Research grants before

From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Univeristy of Texas M.D. Anderson Cancer CenterTexas81$107 million
Sloan-Kettering Institute for Cancer ResearchNew York65$99.1 million
The Trustees of Columbia University in the City of New YorkNew York48$85.3 million
Dana-Farber Cancer Institute, Inc.Massachusetts51$83.1 million
University of North Carolina at Chapel HillNorth Carolina49$76.1 million

Top states: California ($465 million), New York ($445 million), Massachusetts ($350 million), Texas ($259 million), Pennsylvania ($175 million).

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is PAR-25-082 still open?

No. It closed on January 7, 2026.

Who can apply for Co-infection and Cancer (R01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Co-infection and Cancer (R01 Clinical Trial Not Allowed)?

Closed January 7, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

Who has been funded under PAR-25-082?

NIH RePORTER lists 2 projects funded under PAR-25-082 in fiscal 2026, at 2 institutions. The most were at University of TX MD Anderson Can Ctr, Univ of Arkansas for Med Scis.

Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.

Similar open grants